363610-69-9

Upstream product

• 364041-40-7 (2S,3R,4S)-5-(tert-Butyl-diphenyl-silanyloxy)-2,4-dimethyl-pentane-1,3-diol 
• 363610-61-1 (2S,3S,4S,5R)-1-(tert-Butyl-diphenyl-silanyloxy)-3-(4-methoxy-benzyloxy)-2,4-dimethyl-octadecan-5-ol 
• 363610-68-8 (2S,3S,4R,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-3-(4-methoxy-benzyloxy)-2,4-dimethyl-octadecan-1-ol 
• 363610-59-7 (2R,3S,4S)-1-((S)-4-Benzyl-2-thioxo-oxazolidin-3-yl)-5-(tert-butyl-diphenyl-silanyloxy)-3-hydroxy-2,4-dimethyl-pentan-1-one 
• 363610-60-0 (2S,3R,4S)-5-(tert-Butyl-diphenyl-silanyloxy)-3-(4-methoxy-benzyloxy)-2,4-dimethyl-pentan-1-ol 

Relevant academic research and scientific papers

Studies directed towards the synthesis of stevastelins - A macrolactonization approach to stevastelin B

A synthetic approach towards the cyclic depsipeptide immunosuppressant stevastelin B, based on the stereoselective synthesis of its propionate-derived fatty acid segment 6 that was coupled with the tripeptide 7 leading to the advanced stage acyclic intermediate 5, is described. In spite of our best efforts, the crucial macrolactonization reaction was not successful.